london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Pars plana vitrectomy with intravitreal dexamethasone implant for severe diabetic macular edema with taut posterior hyaloid- short term results

Poster Details

First Author: G.Gulkilik TURKEY

Co Author(s):    S. Karaman   M. Ozbek   C. Tanriverdio   G. Demirci   M. Odabasi   M. Ozsutcu   0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To evaluate the effciay of pars plana vitrectomy (PPV) and internal limiting membrane peeling with intravitreal dexamethasone implant (Ozurdex®) in eyes with diffuse diabetic macular edema associated with taut posterior hyaloid.

Setting:

Istanbul Medipol University Department Of Ophthalmology, Istanbul, TURKEY.

Methods:

In this interventional case series 3 eyes of 3 patients with refractory diffuse diabetic macular edema associated with taut posterior hyaloid were evaluated. All eyes had PPV surgery with removal of taut posterior hyaloid and internal limiting membrane peeling. At the end of the surgery all eyes received a single injection Ozurdex. Main outcome measures were change in best corrected visual acuity (BCVA) and central macular thickness (CMT) as measured by spectral domain optical coherence tomography (SD-OCT). Change in intraocular pressure (IOP) was also evaluated.

Results:

Patient 1: Baseline BCVA was counting fingers at 1 meter with a CMT of 950µm with taut posterior hyaloid. One month after the surgery BCVA improved to 0.1 and CMT decreased to 326 µm. BCVA was stable and CMT further decreased to 280 µm during the follow up period of 3 month. Patient 2: BCVA was counting fingers with CMT f 1034 µm with taut posterior hyaloid at baseline. One month after the surgery BCVA improved to 0.05 and CMT decreased to 551 µm. BCVA further increased to 0.1 and CMT decreased to 242 µm during the follow up of 3 months. Patient 3: Baseline BCVA was 0.1 and CMT was 461 µm with taut posterior hyaloid. One month after the surgery BCVA improved to 0.4 and CMT was 324 µm. BCVA further improved to 0.6 and CMT decreased to 260 µm at 3 months. None of the patients had an elevated IOP measurement at any time during the follow up.

Conclusions:

Pars plana vitrectomy with ozurdex implant was safe and effective in the treatment of diffuse diabetic macular edema with taut posterior hyaloid refractory to other treatment modalities. A future prospective controlled study with large number of patients and longer follow up is required to confirm the efficacy and safety of PPV with Ozurdex implant in refractory DME with taut posterior hyaloid.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy